Drug Trial Radar · NCT07321873
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
157
Actual
Start
Jan 15, 2026
Primary completion
Jun 28, 2027
Study completion Aug 2, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.
Conditions
- Arthritis, Psoriatic
Interventions
JNJ-88545223Drug
JNJ-88545223 will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16Time frame: Week 16
Locations
75 sites in 8 countries. Site status is shown where the registry gives one.
Unity Health-White County Medical Center
Searcy, Arkansas
Newport Huntington Medical Group
Huntington Beach, California
Rheumatology Center of San Diego
San Diego, California
Clinical Research of West Florida 1
Clearwater, Florida
American Research, LLC
Cutler Bay, Florida
Innovation Medical Research Center
Palmetto Bay, Florida
Integral Rheumatology And Immunology Specialists
Plantation, Florida
Clinical Research of West Florida
Tampa, Florida
Conquest Research
Winter Park, Florida
Atlanta Research Center for Rheumatology
Marietta, Georgia
Willow Rheumatology and Wellness PLLC
Willowbrook, Illinois
Qualmedica Research
Evansville, Indiana
Albuquerque Rehabilitation and Rheumatology
Albuquerque, New Mexico
Joint and Muscle Research Institute
Charlotte, North Carolina
Onsite Clinical Solutions
Salisbury, North Carolina
Paramount Medical Research & Consulting
Middleburg Heights, Ohio
Clinical Research Philadelphia
Philadelphia, Pennsylvania
Arthritis and Rheumatology Research Institute
Frisco, Texas
Peking University People's Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Tsinghua Changgung Hospital
Beijing, China
Xiangya Hospital Central South University
Changsha, China
Changzhou No 2 Peoples Hospital
Changzhou, China
West China Hospital Sichuan University
Chengdu, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
The Second Affiliated Hospital of Zhejiang University
Hangzhou, China
Ningbo medical center lihuili hospital
Ningbo, China
Shanghai Sixth People's Hospital
Shanghai, China
RHEUMA s r o
Břeclav, Czechia
L K N Arthrocentrum
Hlučín, Czechia
Revmatologicka ambulance
Karvina Frystat, Czechia
Pratia Czech A S
Pardubice, Czechia
Clintrial s r o
Prague, Czechia
Medical Plus Research S R O
Uherské Hradiště, Czechia
Fachklinik Bad Bentheim
Bad Bentheim, Germany
Charite Universitaetsmedizin Berlin
Berlin, Germany
Rheumatologische Schwerpunktpraxis
Berlin, Germany
Praxis Mario Sutowicz
Cottbus, Germany
Hamburger Rheuma Forschungszentrum II
Hamburg, Germany
CAIR Heidelberg
Heidelberg, Germany
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.